

Stephanos Hadziyannis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11588350/publications.pdf>

Version: 2024-02-01

17
papers

3,207
citations

687363

13
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

2062
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. <i>Liver International</i> , 2022, 42, 541-550.	3.9	9
2	Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 243-251.	3.0	4
3	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. <i>Hepatology International</i> , 2013, 7, 88-97.	4.2	136
4	Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2009, 49, 1141-1150.	7.3	418
5	Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a. <i>Gastroenterology</i> , 2009, 136, 2169-2179.e4.	1.3	288
6	Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment. <i>Seminars in Liver Disease</i> , 2006, 26, 130-141.	3.6	230
7	Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2004, 351, 1206-1217.	27.0	1,082
8	Diabetes mellitus and chronic hepatitis C virus infection. <i>Hepatology</i> , 1999, 29, 604-605.	7.3	30
9	Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. <i>Hepatology</i> , 1999, 30, 277-282.	7.3	54
10	Neurovisual impairment: A frequent complication of alpha-interferon treatment in chronic viral hepatitis. <i>Hepatology</i> , 1998, 27, 1421-1427.	7.3	55
11	Delayed Clearance of Serum HBsAg in Compensated Cirrhosis B: Relation to Interferon Alpha Therapy and Disease Prognosis. <i>American Journal of Gastroenterology</i> , 1998, 93, 896-900.	0.4	151
12	The effect of low-dose interferon treatment on visual evoked potentials. <i>Documenta Ophthalmologica</i> , 1997, 94, 215-221.	2.2	8
13	Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: A case-control study. , 1996, 68, 51-53.		45
14	Occurrence of hepatocellular carcinoma and decompensation in western european patients with cirrhosis type B. <i>Hepatology</i> , 1995, 21, 77-82.	7.3	324
15	Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: Importance of host factors. <i>Hepatology</i> , 1995, 22, 1628-1634.	7.3	65
16	Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. <i>Journal of Hepatology</i> , 1994, 21, 656-666.	3.7	283
17	Serum β_2 microglobulin in malignant lymphoproliferative disorders. <i>Cancer</i> , 1985, 55, 2384-2389.	4.1	25